Mesoblast Ltd (MSB)
Australian Securities Exchange · Australia · prices in AUD · close of 19 Oct 2026
Key indicators
| Last close | AUD 1.770 |
|---|---|
| 52-week range | 1.735 – 3.310 |
| Return, 1 month / 3 months | −16.1% / −24.4% |
| Return, 1 year / 3 years | −39.2% / +384.9% |
| Trend | Below its 200-day average |
| RSI (14) | 31 |
| Volatility (1 year) | 55.6% |
| Worst drawdown (1 year) | -42.3% |
| Average daily value traded | 6.13M AUD |
| Dividend yield | – |
Market X-Ray price-based
Five-year price chart navy: price · brown: 200-day average
About the company
Mesoblast is a biopharmaceutical company based in Melbourne that develops off-the-shelf cellular medicines derived from mesenchymal precursor cells. Its product candidates are designed to treat inflammatory and immune-mediated conditions, including graft versus host disease following bone marrow transplantation, chronic heart failure and chronic low back pain. The company works with hospital specialists and clinical researchers to test these cell-based therapies in patients with serious or life-threatening illnesses.
The shares are listed on the Australian Securities Exchange in Australia under the code MSB, and the price on this page is in Australian dollars (AUD). Our records, which start in 2019, show no dividend payments for it. The Market X-Ray on this page is price-based and compares it with other stocks on the same exchange; it does not measure how healthy the business is.
Summary
Mesoblast Ltd (MSB) trades on the Australian Securities Exchange in Australia. It last closed at AUD 1.770 on 19 October 2026.
Its price-based Market X-Ray is 58 out of 100 (a fair price profile), ranking 715 of 1,815 stocks on this exchange. The score describes how the stock has traded: trend, momentum, risk, liquidity and dividends, each ranked against the other stocks on its own exchange. It does not measure how healthy or cheap the business is.
Over the last year the price fell 39.2% and over the last three months it fell 24.4%. Returns are price returns, dividends not included.
Fundamental measures (valuation, growth, financial health) are not shown: we do not yet hold financial statements for this market.
The five lenses in numbers each metric is ranked against the other stocks on Australian Securities Exchange
| Lens and metric | Value | Score | Reading |
|---|---|---|---|
| Trend | 51 · Fair | Mixed trend against its averages. | |
| Above 200-day average | -20.2% | ||
| From 52-week high | -42.3% | ||
| Momentum | 35 · Weak | Lagging most stocks on this exchange. | |
| 3-month return | -24.4% | ||
| 6-month return | -18.8% | ||
| 12-month return, skipping the last month | -27.5% | ||
| Stability (higher is calmer) | 68 · Fair | Typical risk for this exchange. | |
| Volatility, 1 year (lower is calmer) | 55.6% | ||
| Worst drawdown, 1 year (smaller is calmer) | -42.3% | ||
| Liquidity | 89 · Strong | Trades actively. | |
| Average daily value traded | 6.13M AUD | ||
| Zero-volume days | 0.0% | ||
| Income | – | Pays no dividend. | |
| Dividend yield | – | ||
| Years with dividends | 0 |
Strengths
- Liquidity: Trades actively.
Weak spots
- Momentum: Lagging most stocks on this exchange.
Returns
| 1 week | −14.1% |
|---|---|
| 1 month | −16.1% |
| 3 months | −24.4% |
| 6 months | −18.8% |
| 1 year | −39.2% |
| 3 years | +384.9% |
| 5 years | +12.8% |
Signals
| 50-day / 200-day average | 2.192 / 2.218 |
|---|---|
| Golden / death cross (60 days) | None |
| New 52-week high | No |
| Bullish RSI divergence | No |
| Average daily range (ATR) | 0.108 |
Technical summary
How to read this report
Every number comes from end-of-day prices and dividends. The Market X-Ray describes how the stock has traded, ranked against the other stocks on Australian Securities Exchange; it does not measure how healthy or cheap the business is. The fundamental X-Ray (financial health, valuation, growth) needs financial statements, which we hold today for US stocks. See the methodology page. Educational only, not financial advice.